$PYPD Today PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

**$PYPD – FDA just accepted the NDA with Priority Review + $15M milestone triggered. Short-term setup just got a lot hotter**

PolyPid ($PYPD) just hit a major catalyst today (July 29):

FDA accepted the NDA for D-PLEX₁₀₀ and granted **Priority Review**.
PDUFA target action date is now **November 28, 2026** — roughly a full quarter earlier than the previous Q1 2027 guidance.
FDA identified **no filing review issues**.

This acceptance immediately triggers the second $15M milestone from the Azurity partnership, completing the full **$30M** in upfront + near-term payments.

Quick recap of the recent stack:

* Exclusive U.S. & Canada commercialization deal with Azurity (July)
* $15M already received at signing + another $15M now triggered
* Up to \~$300M more in regulatory/development/sales milestones
* Tiered royalties mid-teens to mid-twenties %
* PolyPid keeps manufacturing rights + all rights outside U.S./Canada + full platform ownership

Phase 3 SHIELD II previously delivered the primary endpoint + a 60% relative risk reduction on a key secondary. Breakthrough Therapy, Fast Track, and QIDP designations already in place (which helped secure the Priority Review).

Market cap still sitting in the micro-cap range. Analyst targets have been in the $11–13 area. Next big date on the calendar is now the November 28 PDUFA — and the path just got meaningfully accelerated.

Not financial advice. Biotech is volatile as hell and approval is never guaranteed. Do your own research and size accordingly. Just updating on the fresh FDA acceptance + the cash that just unlocked.

This just got way more interesting!